- Home
- GCMG vs AURA Comparison
GCMG vs AURA Comparison
Compare GCMG & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCMG | AURA |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | 553 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.0M | 713.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GCMG | AURA |
|---|---|---|
| Price | $12.93 | $6.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.33 | ★ $20.00 |
| AVG Volume (30 Days) | 467.0K | ★ 706.0K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.28 | N/A |
| Revenue Next Year | $11.70 | N/A |
| P/E Ratio | $28.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $4.73 |
| 52 Week High | $14.38 | $9.54 |
Technical Indicators
Market Signals| Indicator | GCMG | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 49.92 |
| Support Level | $11.40 | $6.59 |
| Resistance Level | N/A | $7.04 |
| Average True Range (ATR) | 0.47 | 0.51 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 45.57 | 32.09 |
Price Performance
Historical ComparisonAbout GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG, and absolute return strategies. The company invests maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.